Compare · DXCM vs KRMD
DXCM vs KRMD
Side-by-side comparison of DexCom Inc. (DXCM) and KORU Medical Systems Inc. (KRMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DXCM and KRMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $31.50B, about 219.4x KRMD ($143.6M).
- Both names hit the wire about 6 times in the past 4 weeks.
- DXCM has more recent analyst coverage (25 ratings vs 6 for KRMD).
- Company
- DexCom Inc.
- KORU Medical Systems Inc.
- Price
- -
- -
- Market cap
- $31.50B
- $143.6M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2005
- News (4w)
- 6
- 6
- Recent ratings
- 25
- 6
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
KORU Medical Systems Inc.
Repro Med Systems, Inc., doing business as KORU Medical Systems, designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. The company offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. It also provides education and training materials to clinicians, patients, and patient advocates. The company sells its products through direct sales and medical device distributors, as well as online. Repro Med Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer
Latest KRMD
- Director Manko Joseph M. Jr. was granted 5,119 shares (SEC Form 4)
- Director Wholihan Edward was granted 5,119 shares, increasing direct ownership by 10% to 56,431 units (SEC Form 4)
- Director French Donna was granted 5,119 shares, increasing direct ownership by 5% to 103,633 units (SEC Form 4)
- Director Cascella Robert was granted 5,119 shares, increasing direct ownership by 5% to 103,274 units (SEC Form 4)
- Chairman of the Board Fletcher R John was granted 7,679 shares, increasing direct ownership by 3% to 239,836 units (SEC Form 4)
- Director Matin Shahriar was granted 5,119 shares, increasing direct ownership by 5% to 106,263 units (SEC Form 4)
- Chief Commercial Officer Kalbermatten Adam R bought $101,120 worth of shares (32,000 units at $3.16), increasing direct ownership by 9% to 394,017 units (SEC Form 4)
- Chief Commercial Officer Kalbermatten Adam R converted options into 75,000 shares and covered exercise/tax liability with 25,483 shares, increasing direct ownership by 16% to 362,017 units (SEC Form 4) to satisfy withholding obligation
- SEC Form 10-Q filed by KORU Medical Systems Inc.
- KORU Medical Systems Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits